Successful infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in two Taiwanese children: An experience from a medical center
Multiple inflammatory syndrome in children (MIS-C) is a rare, yet serious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated condition that typically presents 2 –6 weeks after infection. MIS-C is believed to result from a delayed hyper-inflammatory reaction to SARS-CoV-2, which leads to an overwhelming cytokine storm [1]. First-tier treatments for MIS-C include intravenous immunoglobulin (IVIG) and glucocorticoids as immune modulators; however, refractory cases may require the use of biologic agents as a second-tier intervention [2–4].
Source: Pediatrics and Neonatology - Category: Perinatology & Neonatology Authors: Chun-Ting Liu, G.W. Gant Luxton, Chia-Cheng Sung, Fu-Min Wang, Chia-Ning Chang, Chih-Fen Hu Source Type: research
More News: Chia | Children | Coronavirus | COVID-19 | Pediatrics | Perinatology & Neonatology | Remicade | Respiratory Medicine | SARS | Taiwan Health